From an article in the Australian dated October 2007: Acrux has...

From an article in the Australian dated October 2007:

Acrux has now partnered KV Pharmaceuticals in the US to launch EvaMist spray by the end of the year with expected annual sales of $US125 million.
"This will generate healthy royalty fees of between $US15 million and $US20 million a year for Acrux and provide strong revenue growth for the company and assist us to profitability."

Full article here: http://www.theaustralian.com.au/bus...er-evamist-spray/story-e6frg8zx-1111114658310

So KV went bankrupt, was renamed to Lumara Health and sold to AMAG Pharma in 2014. Lumara have sub-licensed EvaMist to Perrigo. With all this mess behind it, why doesn't Acrux now see this as an opportunity the way it did back in 2007??? An extra USD 15million a year is not insignificant.